30 Day Trial

Globus Medical Reports Preliminary 4Q15 and 2015 Revenue


Globus Medical announced preliminary unaudited 2015 sales of ~US $544.7MM, +16.0% from 2014, and 4Q15 sales of ~$142.6MM, +11.5% from 4Q14. (Growth reflects constant currency.)

The company established full-year 2016 revenue guidance of $583MM, and an impact of the suspended medical device tax at ~$0.06/share. GMED plans to direct ~40% of this benefit into R&D and manufacturing employment initiatives.

Source: Globus Medical, Inc.

In the next two years, companies with a higher percentage of U.S. sales stand to benefit the most from the device tax suspension. Globus is one of the 17 largest orthopaedic companies with a higher proportion of U.S. sales.